OrbiMed Advisors LLC's Form 4 filing
ARS Pharmaceuticals, Inc. (SPRY) · filed Aug 23, 2024
- Accession no.
- 0000947871-24-000720
- Filed
- Aug 23, 2024, 6:38 PM ET
- Trade date
- Aug 21-23, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $11.5M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director |
| OrbiMed Capital LLCCIK 0001157524 | Director |
| OrbiMed Capital GP VI LLCCIK 0001682115 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 21, 2024 | Common Stock | SSaleDisposed | −394,400 | $13.52 | −$5,332,288 | 557,977 | Indirect | Duplicate filing |
| Aug 21, 2024 | Common Stock | SSaleDisposed | −13,300 | $14.61 | −$194,313 | 544,677 | Indirect | Duplicate filing |
| Aug 22, 2024 | Common Stock | SSaleDisposed | −391,482 | $12.94 | −$5,065,777.08 | 153,195 | Indirect | Duplicate filing |
| Aug 23, 2024 | Common Stock | SSaleDisposed | −69,500 | $13.03 | −$905,585 | 83,695 | Indirect | Duplicate filing |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.